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It is a great honor and pleasure for me to serve as a guest ed-
itor and organize a special issue on Neuroendocrine Tumors.
All the invited authors are well established scientists known
around the world. They made a tremendous contribution here
by overviewing each topic precisely, including a part of their
own data, to cover the topic from the fundamental knowl-
edge to the most up-to-date advancements in the basic and
clinical problems of neuroendocrine tumors.
According to the World Health Organization’s defini-
tion of neuroendocrine tumors, which is morphofunctional
and primarily based on microscopic characteristics including
the identification of hyperfunctioning endocrine tumors [1],
these neoplasms form a diverse group of conditions with a
large spectrum of clinical syndromes depending on the pres-
ence of secreted hormones. Clinical management of neuroen-
docrine tumors is quite challenging with new diagnostic and
therapeutic approaches already available or emerging, espe-
cially after the introduction of genetic screenings that have
led to a significant improvement of patients’ treatment and
counseling. Of course despite our desire it would be impos-
sible to comprehensively cover all the relevant issues, but all
possible attempts were made to address pituitary-related tu-
mors, familiar multiple endocrine neoplasia and some other
diseases involved.
First, an advanced molecular biology analysis of neuroen-
docrine tumors is thoroughly summarized to overcome the
limitations of microarray experiments, inspiring many new
ideas about future directions of molecular studies in neu-
roendocrine tumorigenesis and development of novel ther-
apeutic strategies. For instance, a deep analysis of the RET
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proto-oncogene induced changes gives us not only an under-
standing of the diversity of RET-dependent signal transduc-
tion mechanisms but also warrants a necessity of further in-
vestigation of the genotype-phenotype correlations together
with the development of novel molecular targeting treat-
ment means for multiple endocrine neoplasia. It is notewor-
thy that knowledge of metabolic and signaling pathways of
small molecules in neuroendocrine tumor cells has already
resulted in a successful implementation of therapeutic reg-
imens in cell culture and animal models; progress in the
modulation of the abnormal proteins functioning is strongly
anticipated. From the fundamental research, all reviews in
this issue are intrinsically aimed at clinical applications in
the patients.
Following the first three basic research reviews on neu-
roendocrine tumorigenesis, the specific gene abnormality of
signal transduction is discussed in the two subsequent articles
focusing on an inactivating mutation in the PRKA1A gene
encoding protein kinase A type 1A regulatory subunit in Car-
ney Complex and primary pigmented nodular adrenocortical
disease. The different clinical manifestation and the major
role of cAMP pathway dysregulation in the two diseases are
important to be elucidated, but even such rare neuroendcrine
tumors can give insights into genotype-phenotype relation-
ship as well as into clinical approaches to the appropriate
management of patients.
As one of the ectopic hormone producing neoplasms,
neuroendocrine tumors secreting GHRH are then reviewed
from the standpoint of pathophysiology and clinical aspects.
Although GHRH is infrequently implicated in the pathogen-
esis of acromegaly due to hypothalamic or ectopic hyper-
secretion, reasonable strategy for early and accurate diag-
nosis is essential and clinically needed. Besides the basic
and clinical investigations, more practically oriented genetic
counseling is another important topic that clinicians should
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be aware of, particularly of its psychological impact and eth-
ical complexities in familiar and hereditary neuroendocrine
tumors. Pursuing medical ethics issues, a well-balanced re-
view follows that answers questions commonly arising in
genetic counseling. Recent advancement of tumor imaging
diagnosis for neuroendocrine tumors is also one of the topics
here. Various applications of molecular targeting radiophar-
maceuticals such as FDP and somatostatin receptor imaging
using positron emission tomography are currently available.
Two review articles discuss the benefits and limitations of
diagnosis by tumor imaging for a wide variety of neuroen-
docrine tumors. Precise and more specific molecular target-
ing approaches to functional imaging can be expected to
overcome constraints in the near future, including imple-
mentation of molecular imaging applications for tumors at
different stages. Lastly, the treatment of various neuroen-
docrine tumors with somatostatin analogue is summarized.
The characterization of tumor-specific receptors and appro-
priate use of somatostatin analogue can relieve symptoms
and reduce hormone levels in patients with functioning neu-
roendocrine tumors but reduction in tumor size is unstable
and rather unusual. It is also expected that the new types of
analogues may be more beneficial for treatment.
The markers of final diagnosis of neuroendocrine tumors
are generally accepted to be chromogranins by immunohis-
tochemical staining together with or without visualization
of specific hormones. Neuroendocrine cells are scattered all
over the body from the skin to various internal organs. Further
analysis of the relationship between the identified genotype
and phenotype on histology and clinical course is essentially
needed. This could be done through the establishment of
a wide-ranged global research network of neuroendocrine
tumors using the Chernobyl Tissue Bank [2] as a referring
model of a combination of a collection of biological mate-
rials with a comprehensive database. Although the specific
types of tumors such as carcinoids and non-carcinoid gas-
troenteropancreatic neuroendocrine tumors need to be fur-
ther analyzed separately, all ten topics in this special issue of
Pituitary are timely presented to grasp the current progress
in the area and also to make a link between the knowledge
and technology from bench (etiology, tumor metabolism,
molecular genetics and pathophysiology) to bedside (medi-
cal ethics, diagnosis and treatment).
Finally, the great contribution of the invited authors is
highly appreciated.
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